Neratinib After Adjuvant Therapy Improves Survival in HER2-positive Breast Cancer

Share this content:
Neratinib administered to patients with early stage HER2-positive breast cancer improved 2-year invasive disease-free survival.
Neratinib administered to patients with early stage HER2-positive breast cancer improved 2-year invasive disease-free survival.

Neratinib administered to patients with early stage HER2-positive breast cancer after trastuzumab-based adjuvant therapy for 12 months significantly improved 2-year invasive disease-free survival.1

A total of 2840 women with stage 1 to 3 HER2-positive breast cancer who had completed neoadjuvant and adjuvant trastuzumab therapy up to 1 year prior to randomization were randomly assigned to receive oral neratinib 240 mg per day (n = 1420) or matching placebo (n = 1420). The primary endpoint of this randomized placebo-controlled phase 3 trial was invasive disease-free survival 2 years following randomization.

Results showed that at a median 2-year follow-up, there were 70 invasive disease-free survival events in the neratinib group compared with 109 in the placebo group (stratified HR, 0.67; 95% CI, 0.50 - 0.91; P = .0091). Two-year invasive disease-free survival rate  was 93.9% for neratinib vs 91.6%; 95% CI, 92.4 - 95.2; 95% CI, 90.0 - 93.0, respectively)

Serious adverse events occurred in 7% of patients in the neratinib group vs 6% of patients in the placebo group. The most common grade 3/4 adverse events for patients in the neratinib group were diarrhea (grade 3, 40%; grade 4 < 1% vs 2% grade 3 for placebo), vomiting (grade 3, 3% vs < 1%, respectively) and nausea (grade 3, 2% vs < 1%, respectively). QT prolongation occurred in 3% of patients in the neratinib group vs 7% in the placebo group.

RELATED: Red Blood Cell Transfusion Preferred Over Epoetin Alfa for Treatment of Anemia in Breast Cancer

Seven deaths unrelated to disease progression or treatment occurred after study discontinuation (4, neratinib; 3 placebo). The causes of death for patients receiving neratinib were unknown in 2 patients, a second brain tumor in 1 patient, and acute myeloid leukemia in 1 patient. In the placebo group, causes of death were a brain hemorrhage in 1 patient, myocardial infarction in 1 patient, and gastric cancer in 1 patient.

Investigators concluded that longer follow-up is required to ensure that improvement in outcome is maintained.   

Reference

  1. Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published online ahead of print February 10, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00551-3. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs